Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.50
+0.19
(+2.04%)
After-Hours: 20:00
Monte Rosa Therapeutics Profit Margin (Quarterly) : 5.63% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 5.63% |
| June 30, 2026 | -483.9% |
| March 31, 2026 | -1.06K% |
| December 31, 2025 | -1.66K% |
| September 30, 2025 | -212.1% |
| June 30, 2025 | -53.01% |
| Date | Value |
|---|---|
| March 31, 2025 | 55.20% |
| December 31, 2024 | 22.16% |
| September 30, 2024 | -258.9% |
| June 30, 2024 | -645.6% |
| March 31, 2024 | -3.00K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| United Therapeutics Corp. | 31.06% |
| ACADIA Pharmaceuticals, Inc. | 15.64% |
| Alnylam Pharmaceuticals, Inc. | -- |
| Anika Therapeutics, Inc. | -1.02% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -33.00% |
| Return on Assets | -21.59% |
| Return on Invested Capital | -30.08% |
| Gross Profit Margin (Quarterly) | 96.06% |
| Operating Margin (Quarterly) | -3.57% |
| Return on Net Operating Assets | -205.2% |